What is the new microbiome therapy that could prevent food allergies in newborns?

The new oral microbiome therapy, STMC-103H, developed by researchers at Siolta Therapeutics has shown promising results in a Phase 2 trial, indicating it could reduce the risk of developing food allergies by 77% in newborns with a family history of allergies.

How has the prevalence of peanut allergies changed over time, according to HHS Secretary Robert F. Kennedy?

Secretary Kennedy shared that when he was a child, he never met anyone with a peanut allergy, but by the time his own son was 2 years old, they had been to the emergency room about 22 times due to his severe peanut and other food allergies.

What is the Food Allergy Fund (FAF) doing to investigate the link between gut health and food allergies?

The FAF launched its Food Allergy Fund Microbiome Collective in New York City to further research how gut bacteria could help prevent or treat not only allergies, but also autoimmune and neurodegenerative diseases.

Home / Health / Microbiome Therapy Promises 77% Reduction in Newborn Food Allergies

Microbiome Therapy Promises 77% Reduction in Newborn Food Allergies

18 Nov

•

Summary

Oral microbiome therapy shows promise in preventing food allergies in newborns
Gut health central to overall health, may be linked to rise in food allergies
Peanut allergies far more common today than in the past, experts seek causes

Microbiome Therapy Promises 77% Reduction in Newborn Food Allergies

As of November 2025, health officials and advocates are intensely focused on understanding the root causes behind the growing food allergy crisis in the United States. With over 32 million Americans battling these conditions, the Food Allergy Fund (FAF) recently hosted a forum in Washington, D.C. to explore potential solutions.

At the event, FDA Chief Martin Makary emphasized the central role of gut health, noting that disruptions to the delicate balance of gut microbiomes may be a key driver behind the rise in food allergies. Researchers at Siolta Therapeutics are testing an oral microbiome therapy, STMC-103H, which has shown promising results in a Phase 2 trial involving 238 newborns with a family history of allergies. Early data suggests the therapy could reduce the risk of developing food allergies by 77%, indicating that improving gut bacteria early in life could prevent allergies before they start.